Clinical trials
Cholestasis trials in Canada
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
16 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2006 | 1 |
| 2007 | 1 |
| 2008 | 1 |
| 2010 | 2 |
| 2014 | 1 |
| 2016 | 1 |
| 2017 | 1 |
| 2018 | 2 |
| 2019 | 1 |
| 2020 | 3 |
| 2021 | 1 |
| 2026 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 9 |
| Active, not recruiting | 2 |
| Recruiting | 2 |
| Suspended | 2 |
| Unknown status | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Arbor Research Collaborative for Health | 4 |
| Mirum Pharmaceuticals, Inc. | 3 |
| GlaxoSmithKline | 2 |
| Albireo | 1 |
| Albireo, an Ipsen Company | 1 |
| Boston Scientific Corporation | 1 |
| Children's & Women's Health Centre of British Columbia | 1 |
| Children's Hospital of Eastern Ontario | 1 |
| Cook Group Incorporated | 1 |
| Ibrahim Mohamed | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Cholestasis | 16 |
| Liver Diseases | 4 |
| Alagille Syndrome | 3 |
| Bile Duct Diseases | 3 |
| Biliary Atresia | 2 |
| Biliary Tract Diseases | 2 |
| Digestive System Diseases | 2 |
| Liver Cirrhosis, Biliary | 2 |
| Pruritus | 2 |
| alpha 1-Antitrypsin Deficiency | 2 |
Trials
Showing 51 to 16 of 16. Each trial links to its page on Pharma Observatory.
No trials match these filters.
Try a different keyword, or clear a filter.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.